{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:05:33Z","timestamp":1760299533579},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1985,10]]},"abstract":"<jats:p> We undertook a phase 1 study of Carboplatin (CBDCA) on an intermittent single intravenous (IV) bolus (schedule A) and a 24-hour continuous infusion schedule (schedule B). Hydration and forced diuresis were not performed. Patients were not premedicated for anticipated vomiting. Thirty-eight adult patients with solid tumors received a total of 71 courses. In schedule A, doses were escalated from 20 to 600 mg\/m2. The dose-limiting toxicity was myelosuppression. At doses of 270 mg\/m2 and higher, leukopenia and thrombocytopenia were reproducibly seen. The dose of 600 mg\/m2 was the maximally tolerated dose, producing severe thrombocytopenia (platelet counts less than 30,000\/microL). Other toxicities included a fall in hemoglobin levels and tolerable nausea and vomiting. Schedule B produced comparable hematologic and emetogenic toxicities to those in schedule A. In three patients audiograms became abnormal with high-frequency hearing loss without overt deafness. Two patients developed hypomagnesemia without irreversible renal dysfunction. Patients with poor performance status, preexisting renal dysfunction, a third fluid space, or bone metastases seemed to develop increased hematologic toxicity. The recommended phase 2 dose for good risk patients is 400 mg\/m2 IV bolus and for poor risk patients 270 mg\/m2 IV bolus. Responses were seen in one patient each with head and neck carcinoma (partial response), small cell lung cancer (minor response), and breast cancer (minor response). <\/jats:p>","DOI":"10.1200\/jco.1985.3.10.1385","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T13:18:30Z","timestamp":1487855910000},"page":"1385-1392","source":"Crossref","is-referenced-by-count":42,"title":["Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion."],"prefix":"10.1200","volume":"3","author":[{"given":"S","family":"Leyvraz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lassus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1985.3.10.1385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:34:12Z","timestamp":1653518052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1985.3.10.1385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,10]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1985,10]]}},"alternative-id":["10.1200\/JCO.1985.3.10.1385"],"URL":"https:\/\/doi.org\/10.1200\/jco.1985.3.10.1385","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,10]]}}}